Information Library

Results for: Endocrinology - Phase II/III

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Intarcia and Quintiles Finalize Innovative Alliance

    Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).

  • Clinical – Smarter Trials, Accelerated Outcomes

    Brochure — February 16, 2011
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Exclusive Report From Scientific American

    Hear from the Experts — November 9, 2010
    In-depth insights on every angle of the changing health landscape - brought to you by Quintiles Get the report today.

  • Regulatory Landscapes for Future Antidiabetic Drug Development

    Hear from the Experts — May 12, 2010
    In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.

  • EMA’s Guidance on New Antidiabetic Drug Development

    White Paper — May 12, 2010
    Assessing the EMA’s Guidance on New Antidiabetic Drug Development In January 2010, the European Medicines Agency (EMA) issued a draft guideline on antidiabetic drug development

  • Journal for Clinical Studies

    Hear from the Experts — February 19, 2010
    In the January 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the FDA Guidance on diabetes drugs and cardiovascular risk.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • Early Phase Optimization Strategies

    Media Coverage — November 18, 2009
    As payers balk at rising drug prices and patent expirations threaten the industry’s revenue streams, pharmaceutical companies worldwide are looking for ways to cut costs associated with drug development and, simultaneously, speed the process up.

  • Sub-Saharan Africa Phase II/III Fact Sheet

    Brochure — July 29, 2009
    Sub-Saharan Africa fact sheet about Phase II/III trials. The gateway to Africa: Access to expanded clinical resources and patient populations in South Africa and beyond.

  • Validated Biomarker Menu

    Brochure — July 14, 2009
    A comprehensive menu of validated cell, fluid and tissue based biomarker assays.

Page 1 of 1 (10 results)

Subscribe to Email Based on Your Interests

Set preferences